Brendan Smith
Stock Analyst at TD Cowen
(1.95)
# 3,144
Out of 5,124 analysts
9
Total ratings
50%
Success rate
6.17%
Average return
Main Sectors:
Stocks Rated by Brendan Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVAX Novavax | Maintains: Hold | $8 → $7 | $6.72 | +4.17% | 2 | Nov 4, 2025 | |
| WST West Pharmaceutical Services | Initiates: Buy | $350 | $275.14 | +27.21% | 1 | Oct 29, 2025 | |
| SLP Simulations Plus | Initiates: Hold | $16 | $18.23 | -12.23% | 1 | Sep 30, 2025 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Buy | $3 → $10 | $8.31 | +20.34% | 1 | Sep 20, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $59 → $65 | $67.30 | -3.42% | 2 | Aug 7, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Outperform | n/a | $66.39 | - | 1 | Jul 21, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | n/a | $16.51 | - | 1 | Dec 5, 2022 |
Novavax
Nov 4, 2025
Maintains: Hold
Price Target: $8 → $7
Current: $6.72
Upside: +4.17%
West Pharmaceutical Services
Oct 29, 2025
Initiates: Buy
Price Target: $350
Current: $275.14
Upside: +27.21%
Simulations Plus
Sep 30, 2025
Initiates: Hold
Price Target: $16
Current: $18.23
Upside: -12.23%
Ginkgo Bioworks Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $3 → $10
Current: $8.31
Upside: +20.34%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Buy
Price Target: $59 → $65
Current: $67.30
Upside: -3.42%
Arrowhead Pharmaceuticals
Jul 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $66.39
Upside: -
Denali Therapeutics
Dec 5, 2022
Initiates: Outperform
Price Target: n/a
Current: $16.51
Upside: -